Ziprasidone

General information

Indicated for: Ziprasidone capsule is an atypical antipsychotic. In choosing among treatments, prescribers should be aware of the capacity of ziprasidone capsule to prolong the QT interval and may consider the use of other drugs first ( 1 ) Ziprasidone capsules are indicated for the: • treatment of schizophrenia in adults. ( 1 ) • acute treatment of adults as monotherapy of manic or mixed episodes associated with bipolar I disorder. ( 1 ) • maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate in adults. ( 1 )

Dosing & forms

• Forms/strengths: —
• Frequency: —
• Food: —
• Typical range: 80–160 mg/day (with food)

Mechanism (brief)

D2 and 5‑HT2A antagonism; 5‑HT1A agonism; SNRI activity.

Metabolism & Half‑life

• Metabolism: Aldehyde oxidase, minor CYP3A4.
• Half‑life: ~7 h (IR).

Therapeutic Drug Monitoring (TDM)

Recommended: No

Monitoring highlights

• QTc caution; consider ECG if risk factors — As indicated

In‑depth reading

• QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update. — Psychosomatics (2018)
• Ziprasidone and QTc prolongation: review — Review (2017)

Sources

• Ziprasidone label — DailyMed (2025)